AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...

AstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...

Ossium Health is also running the PRESERVE I trial to evaluate the safety and effectiveness of its deep-frozen bone marrow ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.

AstraZeneca’s Fasenra (benralizumab) met its primary endpoint in the MANDARA trial by demonstrating non-inferiority to the ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...

The stock fell 15% after the consumer goods firm swung to a loss of £96m for the 12 months to the end of May, against a £62m ...

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.

A few months after a key label expansion, AstraZeneca’s asthma treatment Fasenra has received FDA approval to treat a rare ...

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...